news
Nexavar receives final appraisal for primary liver cancer
NICE has released a Final Appraisal Document recommending Nexavar for the treatment of patients with advanced hepatocellular carcinoma...
List view / Grid view
National Institute for Health and Care Excellence (NICE)
news
Bayer receives EU approval for Regorafenib
Bayer have announced the European Commission has granted marketing authorisation for Stivarga...
news
NICE publishes new Parkinson’s clinical guidance
Parkinson’s disease is one of the most common neurological conditions, affecting an estimated 130,000 people in the UK, with an annual incidence of around 15-20 per 100,000. It mainly affects people aged 50 or over.
news
NICE approves 3 drugs for treating plaque psoriasis in children
NICE has approved adalimumab (Humira, AbbVie), etanercept (Enbrel, Pfizer) and ustekinumab (Stelara, Janssen) for treating plaque psoriasis in children...
news
New improved BNF and BNFC app launched
The British National Formulary (BNF) and British National Formulary for Children (BNFC) have launched a new, faster, easier to use app...
news
NICE recommends cabozantinib for advanced renal cell cancer
The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending cabozantinib for some kidney cancer patients
news
NICE recommends Lilly’s Baricitinib (Olumiant) to treat rheumatoid arthritis
Baricitinib is the first JAK inhibitor to be recommended by NICE to treat rheumatoid arthritis in adults who have not responded to conventional therapy…
news
NICE approves AstraZeneca’s COPD drug
The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending roflumilast (Daxas, AstraZeneca) for chronic obstructive pulmonary disease (COPD).
news
Kadcyla new deal means NICE positive recommendation in draft guidance
A new deal on the breast cancer drug trastuzumab emtansine means that it can now be recommended for routine funding.
news
NICE recommends Lilly’s Olaratumab (Lartruvo) to treat sarcoma
Olaratumab is the first monoclonal antibody, in combination with doxorubicin, to be recommended for the treatment of advanced soft tissue sarcoma.
news
NICE recommends Janssen’s Crohn’s Disease biological therapy
2 May 2017 | By Niamh Marriott, Junior Editor
NICE has recommended Stelara (ustekinumab) in its final appraisal determination as a treatment option for adult patients with Crohn’s disease...
news
NICE does not recommend Janssen’s multiple myeloma drug
29 March 2017 | By Niamh Marriott, Junior Editor
NICE) has published new draft guidance not recommending daratumumab monotherapy (Darzalex, Janssen) to treat some people with multiple myeloma...
news
Price drops make more cancer drugs routinely available
7 March 2017 | By Steve Bremer, Managing Editor
The National Institute for Health and Care Excellence (NICE) is half way through a review of drugs approved and still available only through the old Cancer Drugs Fund (CDF). In all cases so far where NICE has been able to make recommendations for routine NHS use, companies have reviewed and…
news
NICE does not recommend Merck’s lung cancer drug
2 March 2017 | By Niamh Marriott, Digital Editor
NICE has published draft guidance which does not recommend Keytruda, also known as pembrolizumab, for untreated PD-L1-positive metastatic lung cancer...
article
UPDATE: The Cancer Drugs Fund
1 March 2017 | By Niamh Louise Marriott, Digital Editor
This page will be updated as the results from the Cancer Drugs Fund appraisal are announced by The National Institute of Health and Care Excellence (NICE).
